Hoth Therapeutics (NASDAQ:HOTH) shares rose by a staggering 215% today following significant breakthrough in cancer treatment. Their Phase 2a clinical trial of Hoth's topical gel HT-001 has shown 100% ...
Hoth Therapeutics Inc. HOTH on Tuesday revealed preclinical data from its study on glial cell-derived neurotrophic factor ...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today announced compelling preclinical data from its ...
In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA ...
NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has ...
NEW YORK, April 12, 2021 /PRNewswire/ — Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results